{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:47Z","timestamp":1761895967304,"version":"3.40.5"},"reference-count":160,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","derm.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.det.2014.09.010","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T09:45:26Z","timestamp":1416303926000},"page":"127-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Psoriatic Arthritis for the Dermatologist"],"prefix":"10.1016","volume":"33","author":[{"given":"Suzanne J.","family":"Tintle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.det.2014.09.010_bib4","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib6","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14712598.2014.890587","article-title":"Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis","volume":"14","author":"Weitz","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial aggregation of psoriatic arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0198-8859(98)00123-2","article-title":"HLA-C locus alleles in patients with psoriatic arthritis (PsA)","volume":"60","author":"Gladman","year":"1999","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib11","doi-asserted-by":"crossref","first-page":"e1000041","DOI":"10.1371\/journal.pgen.1000041","article-title":"A\u00a0genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci","volume":"4","author":"Liu","year":"2008","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-014-0414-y","article-title":"The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment","volume":"16","author":"Frleta","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.det.2014.09.010_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrrheum.2009.210","article-title":"The diagnosis and treatment of early psoriatic arthritis","volume":"5","author":"Anandarajah","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.bor.0000167752.93543.76","article-title":"Pathogenesis of psoriatic arthritis","volume":"17","author":"Ritchlin","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.det.2014.09.010_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pathol-011110-130318","article-title":"The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin","volume":"8","author":"Weaver","year":"2013","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"1\u20132","key":"10.1016\/j.det.2014.09.010_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.det.2014.09.010_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","author":"Adamopoulos","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-012-0259-1","article-title":"Altered bone biology in psoriatic arthritis","volume":"14","author":"Rahimi","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.det.2014.09.010_bib21","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3899\/jrheum.090510","article-title":"Juvenile psoriatic arthritis: bathwater or baby?","volume":"36","author":"Nigrovic","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/09546631003801601","article-title":"Combination systemic therapies in psoriatic arthritis","volume":"22","author":"Daly","year":"2011","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2010.02.061","article-title":"Recognizing psoriatic arthritis in the dermatology clinic","volume":"63","author":"Garg","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib25","first-page":"757","article-title":"Risk factors for the development of psoriatic arthritis: a population based nested case control study","volume":"29","author":"Thumboo","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib26","first-page":"2638","article-title":"Clinical and genetic aspects of psoriatic arthritis \u201csine psoriasis\u201d","volume":"30","author":"Scarpa","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/09546630600967166","article-title":"Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study","volume":"17","author":"Gottlieb","year":"2006","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib29","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","article-title":"Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis","volume":"160","author":"Reich","year":"2009","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.det.2014.09.010_bib30","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2165\/00003495-200262170-00004","article-title":"Diagnosis and management of psoriatic arthritis","volume":"62","author":"Brockbank","year":"2002","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1529-8019.2010.01306.x","article-title":"Psoriatic arthritis","volume":"23","author":"Wollina","year":"2010","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib32","first-page":"62","article-title":"Reliability of measurements of active and damaged joints in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12016-012-8304-4","article-title":"Imaging in psoriatic arthritis","volume":"44","author":"Anandarajah","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"10.1016\/j.det.2014.09.010_bib35","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.det.2014.09.010_bib36","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.det.2014.09.010_bib37","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.4049\/jimmunol.1102834","article-title":"Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants","volume":"188","author":"Thorleifsdottir","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrmicro2537","article-title":"The skin microbiome","volume":"9","author":"Grice","year":"2011","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/ard.2007.073932","article-title":"Environmental risk factors for the development of psoriatic arthritis: results from a case-control study","volume":"67","author":"Pattison","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/ard.2010.147793","article-title":"The association between smoking and the development of psoriatic arthritis among psoriasis patients","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","article-title":"Obesity in early adulthood as a risk factor for psoriatic arthritis","volume":"146","author":"Soltani-Arabshahi","year":"2010","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2340\/0001555576467471","article-title":"Association of psychic stress with clinical severity and symptoms of psoriatic patients","volume":"76","author":"Harvima","year":"1996","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.reuma.2010.03.003","article-title":"Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics","volume":"7","author":"Freire","year":"2011","journal-title":"Reumatol Clin"},{"issue":"9504","key":"10.1016\/j.det.2014.09.010_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.det.2014.09.010_bib47","first-page":"52","article-title":"Laboratory findings in psoriatic arthritis","volume":"59","author":"Punzi","year":"2007","journal-title":"Reumatismo"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.det.2014.09.010_bib49","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.det.2014.09.010_bib50","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib51","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib53","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.det.2014.09.010_bib54","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2014.09.010_bib56","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib57","first-page":"1431","article-title":"Therapies for axial disease in psoriatic arthritis. A systematic review","volume":"33","author":"Nash","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd1607","article-title":"Psoriasis: emerging therapeutic strategies","volume":"4","author":"Gottlieb","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1759720X13501021","article-title":"Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential","volume":"5","author":"Gottlieb","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.det.2014.09.010_bib60","doi-asserted-by":"crossref","unstructured":"Ritchlin CM, IK A, Puig L, et\u00a0al. Maintenance of efficacy and safety of ustekinumab in patients with active psoriatic arthritis despite prior conventional nonbiologic and anti-TNF biologic therapy: 1 year results of a phase 3, multicenter, double-blind, placebo-controlled trial. American College of Rheumatology\/ARHP Annual Meeting. San Diego, October 26\u201330, 2013.","DOI":"10.1136\/annrheumdis-2013-eular.206"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib61","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1052-5157(18)30351-9","article-title":"Nonsteroidal anti-inflammatory drug gastropathy","volume":"6","author":"Laine","year":"1996","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","article-title":"Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure","volume":"169","author":"Gislason","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.1780150205","article-title":"Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide","volume":"15","author":"McCarty","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib65","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/acr.21947","article-title":"Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era","volume":"65","author":"Papadopoulou","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2001.117047","article-title":"Treatment of psoriasis. Part 2. Systemic therapies","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2014.09.010_bib67","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A\u00a0randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib68","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib69","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib70","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib72","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 11","key":"10.1016\/j.det.2014.09.010_bib74","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1002\/art.38455","article-title":"A39: efficacy and safety of methotrexate in oligoarticular persistent juvenile idiopathic arthritis","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib75","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib76","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib77","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib78","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2014.09.010_bib79","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.det.2014.09.010_bib80","first-page":"2274","article-title":"A\u00a0comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib81","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib82","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaad.2004.07.043","article-title":"Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature","volume":"52","author":"Dadlani","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.det.2014.09.010_bib85","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.det.2014.09.010_bib86","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib87","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib88","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A\u00a0randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2014.09.010_bib89","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3899\/jrheum.120251","article-title":"Adalimumab in psoriatic arthritis","volume":"89","author":"Salvarani","year":"2012","journal-title":"J\u00a0Rheumatol Suppl"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib90","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib91","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9494","key":"10.1016\/j.det.2014.09.010_bib92","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.det.2014.09.010_bib93","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.det.2014.09.010_bib94","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib95","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib97","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1111\/j.1468-3083.2012.04716.x","article-title":"Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study","volume":"27","author":"Papp","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib98","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib99","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2014.09.010_bib101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1546-0096-8-24","article-title":"The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial","volume":"8","author":"Visvanathan","year":"2010","journal-title":"Pediatr Rheumatol Online\u00a0J"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib102","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynjala","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.det.2014.09.010_bib104","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of the RAPID-PsA study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.det.2014.09.010_bib105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrrheum.2011.125","article-title":"Management of psoriatic arthritis from the view of the dermatologist","volume":"7","author":"Chang","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib106","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12325-014-0110-3","article-title":"Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a us managed care sample","volume":"31","author":"Yeaw","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.det.2014.09.010_bib107","first-page":"417","article-title":"Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis","volume":"6","author":"Thorlund","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.det.2014.09.010_bib108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2474-15-25","article-title":"Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies","volume":"15","author":"Lubrano","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"10.1016\/j.det.2014.09.010_bib109","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A\u00a0randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib110","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1002\/art.24128","article-title":"Investigation of association of the IL12B and IL23R genes with psoriatic arthritis","volume":"58","author":"Filer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib111","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib112","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2249.1998.00485.x","article-title":"Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis","volume":"111","author":"Malfait","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"9664","key":"10.1016\/j.det.2014.09.010_bib113","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.det.2014.09.010_bib114","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib116","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2013.01.011","article-title":"Major cardiovascular events associated with anti-IL 12\/23 agents: a tale of two meta-analyses","volume":"68","author":"Dommasch","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib117","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.13013","article-title":"Demography, baseline disease characteristics, and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR)","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/17512433.2014.904200","article-title":"Apremilast for the treatment of psoriatic arthritis","volume":"7","author":"Varada","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cytogfr.2012.10.001","article-title":"The emerging role of interleukin 27 in inflammatory arthritis and bone destruction","volume":"24","author":"Adamopoulos","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"10.1016\/j.det.2014.09.010_bib121","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naive or TNF-IR patients with rheumatoid arthritis","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"10.1016\/j.det.2014.09.010_bib122","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"52","key":"10.1016\/j.det.2014.09.010_bib123","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/08916934.2010.517815","article-title":"Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis","volume":"44","author":"Chao","year":"2011","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.det.2014.09.010_bib127","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib128","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib129","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2014.09.010_bib130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2014.09.010_bib131","unstructured":"Available at: http:\/\/www.skinandallergynews.com\/news\/conference-news\/american-academy-of-dermatology-annual-meeting-2013\/single-article\/psoriasis-drug-mk-3222-progresses-through-pipeline\/eab1780ca1924cf44d735207b8823054.html. Accessed December 7, 2013. WSPdM-ptpSAN."},{"key":"10.1016\/j.det.2014.09.010_bib132","article-title":"Secukinumab soars in phase III psoriasis studies","volume":"2013","author":"Jancin","year":"2013","journal-title":"Rheumatology News Online"},{"key":"10.1016\/j.det.2014.09.010_bib133","article-title":"Psoriasis drug MK-3222 progresses through pipeline","author":"SW","year":"2013","journal-title":"Skin Allergy News"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib134","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9636","key":"10.1016\/j.det.2014.09.010_bib135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.det.2014.09.010_bib136","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to jak kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib137","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/eci.12.19","article-title":"Tofacitinib for the treatment of rheumatoid arthritis","volume":"8","author":"Zerbini","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib138","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.det.2014.09.010_bib139","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaad.2013.08.042","article-title":"Research gaps in psoriasis: opportunities for future studies","volume":"70","author":"Ryan","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib141","first-page":"137","article-title":"Early psoriatic arthritis: the clinical spectrum","volume":"35","author":"Scarpa","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib142","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A\u00a0randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis","volume":"64","author":"Fraser","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib143","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib144","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib145","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib146","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/rheumatology\/ken467","article-title":"Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register","volume":"48","author":"Kristensen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib147","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2010.130864","article-title":"Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study","volume":"70","author":"Atzeni","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib148","first-page":"725","article-title":"Musculoskeletal surgery in psoriatic arthritis","volume":"25","author":"Zangger","year":"1998","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib149","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991","volume":"27","author":"Shbeeb","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2014.09.010_bib150","first-page":"919","article-title":"Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus","volume":"27","author":"Zangger","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib151","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib152","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A\u00a0randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4 Suppl 78","key":"10.1016\/j.det.2014.09.010_bib153","first-page":"S63","article-title":"Continuous versus intermittent therapy for moderate-to-severe psoriasis","volume":"31","author":"Ramirez-Fort","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2014.09.010_bib154","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7861\/clinmedicine.14-1-95","article-title":"Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey","volume":"14","author":"Jani","year":"2014","journal-title":"Clin Med"},{"key":"10.1016\/j.det.2014.09.010_bib155","article-title":"Current concepts in psoriatic arthritis: pathogenesis and management","author":"de Vlam","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.det.2014.09.010_bib156","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjcard.2008.10.004","article-title":"AJC editor's consensus: psoriasis and coronary artery disease","volume":"102","author":"Friedewald","year":"2008","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib157","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2014.09.010_bib158","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","article-title":"Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2014.09.010_bib159","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-4632.2011.05424.x","article-title":"Ocular findings in patients with psoriasis","volume":"52","author":"Kilic","year":"2013","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2014.09.010_bib160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.rdc.2012.08.010","article-title":"Comorbidities in patients with spondyloarthritis","volume":"38","author":"van der Horst-Bruinsma","year":"2012","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863514001168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863514001168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:13:17Z","timestamp":1747163597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863514001168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0733863514001168"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2014.09.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic Arthritis for the Dermatologist","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2014.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}